{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T00:53:17Z","timestamp":1794012797126,"version":"4.8.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,17]],"date-time":"2023-12-17T00:00:00Z","timestamp":1702771200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009888","name":"Regione Toscana","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009888","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015694","name":"Fondazione Cassa di Risparmio di Firenze","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007366","name":"Fondazione Italiana Sclerosi Multipla","doi-asserted-by":"publisher","award":["2014\/R\/6"],"award-info":[{"award-number":["2014\/R\/6"]}],"id":[{"id":"10.13039\/100007366","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007366","name":"Fondazione Italiana Sclerosi Multipla","doi-asserted-by":"publisher","award":["2022\/R-Single\/023"],"award-info":[{"award-number":["2022\/R-Single\/023"]}],"id":[{"id":"10.13039\/100007366","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["20451"],"award-info":[{"award-number":["20451"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.nbd.2023.106387","type":"journal-article","created":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T11:44:14Z","timestamp":1703245454000},"page":"106387","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["The mitochondriogenic but not the immunosuppressant effects of mTOR inhibitors prompt neuroprotection and delay disease evolution in a mouse model of progressive multiple sclerosis"],"prefix":"10.1016","volume":"191","author":[{"given":"Daniela","family":"Buonvicino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Pratesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Ranieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Pistolesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Guasti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Chiarugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.nbd.2023.106387_bb0005","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/sj.bjp.0707288","article-title":"Mitochondrial medicine: pharmacological targeting of mitochondria in disease","volume":"151","author":"Armstrong","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.nbd.2023.106387_bb0010","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.msard.2018.08.009","article-title":"Promising effect of rapamycin on multiple sclerosis","volume":"26","author":"Bagherpour","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"15","key":"10.1016\/j.nbd.2023.106387_bb0015","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1007\/s40265-018-0984-5","article-title":"Therapeutic advances and challenges in the treatment of progressive multiple sclerosis","volume":"78","author":"Baldassari","year":"2018","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.nbd.2023.106387_bb0020","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1172\/JCI33464","article-title":"Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis","volume":"118","author":"Basso","year":"2008","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.nbd.2023.106387_bb0025","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s12031-008-9115-1","article-title":"Variations in mitochondrial DNA copy numbers in MS brains","volume":"35","author":"Blokhin","year":"2008","journal-title":"J. Mol. Neurosci."},{"issue":"10","key":"10.1016\/j.nbd.2023.106387_bb0030","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1097\/j.pain.0000000000001291","article-title":"Trigeminal ganglion transcriptome analysis in 2 rat models of medication-overuse headache reveals coherent and widespread induction of pronociceptive gene expression patterns","volume":"159","author":"Buonvicino","year":"2018","journal-title":"Pain"},{"key":"10.1016\/j.nbd.2023.106387_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2019.113065","article-title":"Neuroimmunological characterization of a mouse model of primary progressive experimental autoimmune encephalomyelitis and effects of immunosuppressive or neuroprotective strategies on disease evolution","volume":"322","author":"Buonvicino","year":"2019","journal-title":"Exp. Neurol."},{"issue":"14","key":"10.1016\/j.nbd.2023.106387_bb0040","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1111\/bph.15058","article-title":"Neuroprotection induced by dexpramipexole delays disease progression in a mouse model of progressive multiple sclerosis","volume":"177","author":"Buonvicino","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.nbd.2023.106387_bb0045","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.neuroscience.2021.04.002","article-title":"Treatment with non-specific HDAC inhibitors administered after disease onset does not delay evolution in a mouse model of progressive multiple sclerosis","volume":"465","author":"Buonvicino","year":"2021","journal-title":"Neurosci."},{"key":"10.1016\/j.nbd.2023.106387_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2023.106015","article-title":"Early derangement of axonal mitochondria occurs in a mouse model of progressive but not relapsing-remitting multiple sclerosis","volume":"178","author":"Buonvicino","year":"2023","journal-title":"Neurobiol. Dis."},{"issue":"7","key":"10.1016\/j.nbd.2023.106387_bb0055","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/1873-3468.13013","article-title":"Mitochondrial dysfunction and axon degeneration in progressive multiple sclerosis","volume":"592","author":"Campbell","year":"2018","journal-title":"FEBS Lett."},{"issue":"3","key":"10.1016\/j.nbd.2023.106387_bb0060","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/ana.22109","article-title":"Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis","volume":"69","author":"Campbell","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2023.106387_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2019.05.012","article-title":"Targeting mitochondria to protect axons in progressive MS","volume":"710","author":"Campbell","year":"2019","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.nbd.2023.106387_bb0070","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.bbi.2015.06.019","article-title":"Dysregulation of sphingosine 1 phosphate receptor-1 (S1P1) signaling and regulatory lymphocyte-dependent immunosuppression in a model of post-fingolimod MS rebound","volume":"50","author":"Cavone","year":"2015","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.nbd.2023.106387_bb0075","first-page":"107971","article-title":"Lessons from S1P receptor targeting in multiple sclerosis","author":"Colombo","year":"2021","journal-title":"Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.nbd.2023.106387_bb0080","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/bph.14153","article-title":"Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers","volume":"175","author":"Curtis","year":"2018","journal-title":"Br. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.nbd.2023.106387_bb0085","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1365-3083.2010.02451.x","article-title":"Specific and strain-independent effects of dexamethasone in the prevention and treatment of experimental autoimmune encephalomyelitis in rodents","volume":"72","author":"Donia","year":"2010","journal-title":"Scand. J. Immunol."},{"issue":"5","key":"10.1016\/j.nbd.2023.106387_bb0090","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/FTD.0000000000000628","article-title":"Therapeutic drug monitoring of Everolimus in oncology: evidences and perspectives","volume":"41","author":"Falkowski","year":"2019","journal-title":"Ther. Drug Monit."},{"issue":"9","key":"10.1016\/j.nbd.2023.106387_bb0095","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/ni.1775","article-title":"Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE","volume":"10","author":"Farez","year":"2009","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.nbd.2023.106387_bb0100","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.neuropharm.2017.01.039","article-title":"Post onset, oral rapamycin treatment delays development of mitochondrial encephalopathy only at supramaximal doses","volume":"117","author":"Felici","year":"2017","journal-title":"Neuropharmacol."},{"issue":"13","key":"10.1016\/j.nbd.2023.106387_bb0105","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21134570","article-title":"Quantitative ultrastructural morphometry and gene expression of mTOR-related Mitochondriogenesis within glioblastoma cells","volume":"21","author":"Ferese","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.nbd.2023.106387_bb0110","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1093\/intimm\/dxl080","article-title":"A BAFF antagonist suppresses experimental autoimmune encephalomyelitis by targeting cell-mediated and humoral immune responses","volume":"18","author":"Huntington","year":"2006","journal-title":"Int. Immunol."},{"issue":"1","key":"10.1016\/j.nbd.2023.106387_bb0115","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0165-5728(99)00153-8","article-title":"Anti-IL-12 antibody prevents the development and progression of multiple sclerosis-like relapsing--remitting demyelinating disease in NOD mice induced with myelin oligodendrocyte glycoprotein peptide","volume":"102","author":"Ichikawa","year":"2000","journal-title":"J. Neuroimmunol."},{"issue":"6165","key":"10.1016\/j.nbd.2023.106387_bb0120","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1126\/science.1244360","article-title":"mTOR inhibition alleviates mitochondrial disease in a mouse model of Leigh syndrome","volume":"342","author":"Johnson","year":"2013","journal-title":"Sci."},{"issue":"7","key":"10.1016\/j.nbd.2023.106387_bb0125","doi-asserted-by":"crossref","first-page":"124","DOI":"10.17116\/jnevro2021121071124","article-title":"Siponimod: a new view at the therapy of secondary progressive multiple sclerosis","volume":"121","author":"Krasnov","year":"2021","journal-title":"Zh. Nevrol. Psikhiatr. Im. S S Korsakova"},{"issue":"8","key":"10.1016\/j.nbd.2023.106387_bb0130","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s40265-020-01319-7","article-title":"Ozanimod: first approval","volume":"80","author":"Lamb","year":"2020","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.nbd.2023.106387_bb0135","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26061592","article-title":"Neuroprotective effects of Thymoquinone by the modulation of ER stress and apoptotic pathway in in vitro model of excitotoxicity","volume":"26","author":"Landucci","year":"2021","journal-title":"Molecules"},{"issue":"Pt 7","key":"10.1016\/j.nbd.2023.106387_bb0140","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1093\/brain\/aww113","article-title":"IL-10-dependent Tr1 cells attenuate astrocyte activation and ameliorate chronic central nervous system inflammation","volume":"139","author":"Mayo","year":"2016","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.nbd.2023.106387_bb0145","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.pneurobio.2010.06.005","article-title":"Animal models of multiple sclerosis--potentials and limitations","volume":"92","author":"Mix","year":"2010","journal-title":"Prog. Neurobiol."},{"issue":"7","key":"10.1016\/j.nbd.2023.106387_bb0150","first-page":"813","article-title":"Sirolimus and mTOR inhibitors: a review of side effects and specific management in solid organ transplantation","volume":"42","author":"Nguyen","year":"2019","journal-title":"Drug Saf."},{"issue":"6","key":"10.1016\/j.nbd.2023.106387_bb0155","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1159\/000342204","article-title":"Metabolic regulation, mitochondria and the life-prolonging effect of rapamycin: a mini-review","volume":"58","author":"Pan","year":"2012","journal-title":"Gerontol."},{"issue":"6","key":"10.1016\/j.nbd.2023.106387_bb0160","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jhep.2020.12.031","article-title":"Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma","volume":"74","author":"Raggi","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.nbd.2023.106387_bb0165","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.61798","article-title":"Enhancing mitochondrial activity in neurons protects against neurodegeneration in a mouse model of multiple sclerosis","volume":"10","author":"Rosenkranz","year":"2021","journal-title":"Elife"},{"issue":"8","key":"10.1016\/j.nbd.2023.106387_bb0170","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1073\/pnas.1615413114","article-title":"Sphingosine 1-phosphate receptor modulation suppresses pathogenic astrocyte activation and chronic progressive CNS inflammation","volume":"114","author":"Rothhammer","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9","key":"10.1016\/j.nbd.2023.106387_bb0175","first-page":"629","article-title":"Recommendations of everolimus use in liver transplant","volume":"40","author":"Rubin Suarez","year":"2017","journal-title":"Gastroenterol. Hepatol."},{"issue":"Pt B","key":"10.1016\/j.nbd.2023.106387_bb0180","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.neuropharm.2015.08.028","article-title":"Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis","volume":"110","author":"Sedel","year":"2016","journal-title":"Neuropharmacol."},{"issue":"1","key":"10.1016\/j.nbd.2023.106387_bb0185","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.cell.2017.03.001","article-title":"Selective chemical inhibition of PGC-1alpha Gluconeogenic activity ameliorates type 2 diabetes","volume":"169","author":"Sharabi","year":"2017","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.nbd.2023.106387_bb0190","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrneurol.2016.37","article-title":"Multiple sclerosis: fingolimod failure in progressive MS INFORMS future trials","volume":"12","author":"Smith","year":"2016","journal-title":"Nat. Rev. Neurol."},{"issue":"5","key":"10.1016\/j.nbd.2023.106387_bb0195","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/nri2546","article-title":"Immunoregulatory functions of mTOR inhibition","volume":"9","author":"Thomson","year":"2009","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.nbd.2023.106387_bb0200","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S1474-4422(09)70043-2","article-title":"Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis","volume":"8","author":"Trapp","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.nbd.2023.106387_bb0205","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3389\/fphar.2019.00286","article-title":"Targeting microglia and macrophages: a potential treatment strategy for multiple sclerosis","volume":"10","author":"Wang","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.nbd.2023.106387_bb0210","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.molmed.2013.11.007","article-title":"Mitochondrial dysfunction contributes to neurodegeneration in multiple sclerosis","volume":"20","author":"Witte","year":"2014","journal-title":"Trends Mol. Med."},{"issue":"11","key":"10.1016\/j.nbd.2023.106387_bb0215","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1016\/j.apsb.2021.03.026","article-title":"Pharmacological insights into autophagy modulation in autoimmune diseases","volume":"11","author":"Wu","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.nbd.2023.106387_bb0220","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.13378","article-title":"Alleviation of neuronal energy deficiency by mTOR inhibition as a treatment for mitochondria-related neurodegeneration","volume":"5","author":"Zheng","year":"2016","journal-title":"Elife"}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996123004035?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996123004035?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T05:39:07Z","timestamp":1760852347000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969996123004035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":44,"alternative-id":["S0969996123004035"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2023.106387","relation":{},"ISSN":["0969-9961"],"issn-type":[{"value":"0969-9961","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The mitochondriogenic but not the immunosuppressant effects of mTOR inhibitors prompt neuroprotection and delay disease evolution in a mouse model of progressive multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nbd.2023.106387","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106387"}}